News: Biocept Inc (NASDAQ:BIOC) belongs to Healthcare sector and Medical Laboratories & Research industry. Biocept, Inc. (NASDAQ: BIOC), a main business supplier of clinically significant fluid biopsy tests intended to enhance the results of malignancy patients, pronounces that it has secured an in-system supplier concurrence with Blue Cross Blue Shield of Texas (BCBSTX), the main supplier of medical advantages in that state.
“Deciding the sub-atomic status of a tumor can help doctors individualize treatment for their patients and our profoundly touchy Target Selector™ stage can give this imperative data from a basic blood test,” said Biocept’s Senior Vice President and Senior Medical Director Veena Singh, MD. “Our fluid biopsy testing is changing the way doctors assess tumor status and screen both reaction and imperviousness to treatment.”
“It is satisfying that wellbeing arrangements are seeing the estimation of our fluid biopsy approach for profiling and checking vital tumor biomarkers,” said Michael Nall, President and Chief Executive Officer of Biocept. “Collaborating with wellbeing guarantors is a noteworthy concentration of our business system, as it might expand doctor access to this non-intrusive innovation for their patients and give opportune settling of cases to patients. Securing this in-system assention is a vital turning point for Biocept, as Texas is one of our driving markets and BCBSTX is the main supplier in that state. With this understanding, the quantity of patients with in-system access to our tests has developed to around 185 million, with a few individuals having admittance by means of numerous arrangements.”
Summary: Biocept, Inc. is a molecular diagnostics organization with popularized measures for lung, bosom, gastric, colorectal and prostate malignancies, and melanoma. The Company utilizes its restrictive fluid biopsy innovation to give doctors with data to treating and checking patients determined to have disease. The Company’s licensed Target Selector™ fluid biopsy innovation stage catches and dissects tumor-related sub-atomic markers in both flowing tumor cells (CTCs) and in plasma (ctDNA). With a great many tests played out, the stage has shown the capacity to recognize growth changes and adjustments to advise doctors about a patient’s sickness and restorative choices.